The trend toward larger deal sizes is likely to continue as companies seek to bolster their pipelines amid a looming patent cliff for many drug developers.

The conference runs from Monday through Thursday after two years of unprecedented underperformance for the healthcare sector.

As the healthcare and life sciences industry gears up for the highly anticipated JP Morgan Healthcare Conference later this month, stakeholders